Day: April 1, 2021

産後ケア施設、病院、薬局チェーンのほか、ジョイントベンチャーパートナーがサービスを提供するオンラインプラットフォームの広範なネットワークを通じてPeriCoachを販売予定。 さらにジョイントベンチャーは、100都市に3万人以上の臨床医を擁する広範なネットワークを活用して中国でPeriCoachを販売。 アナリティカの既存の中東販売パートナーシップを基盤に構築された本契約を通じて、国際市場でPeriCoachの成長と製造を促進。 臨床試験では、非監視型PeriCoach療法に、はるかに低コストながら腹圧性尿失禁治療の院内骨盤底物理療法と同等の有効性を確認。 PeriCoachは、分娩後および高齢者に向けて、生活の質の向上、治療負担の軽減、尿失禁パッド支出の削減に費用対効果の高いソリューションを提供。オーストラリア、ブリスベン発, April 01, 2021 (GLOBE NEWSWIRE) — 腹圧性尿失禁治療用にPeriCoach骨盤底筋運動システムを製造するオーストラリアのメーカーであるアナリティカ (Analytica Limited) (ASX:ALT) は、中国、マカオ、香港、台湾でシステムを製造、流通、販売するジョイントベンチャー (JV) 契約を締結した。アナリティカは、河北省に本社を置く河北NACOLバイオテクノロジー (Hebei NACOL Bio-Technology Co., Ltd、以下「Nacol」) と石家荘バイオスフィア (Shijiazhuang Biosphere Pty Ltd、以下「バイオスフィア」) と提携する。 Nacolの主要株主には、中国の経験豊富な医療機器製造販売企業である河北アイネンバイオテクノロジー (Heibei Aineng Biological Technology Co., Ltd) と石家荘YST医療用品 (Shijiazhuang YST Medical Supplies Co....

PeriCoach, 합작 파트너사들이 고객사로 보유하고 있는 광범위한 산후조리원, 병원, 약국 체인, 온라인 플랫폼 네트워크를 통해 유통될 예정 합작법인은 중국 내 PeriCoach 유통을 위해 100여 도시 내 3만 명 이상의 임상 전문가 네트워크 활용 기존에 구축된 중동 지역 유통 파트너십 활용해 PeriCoach의 해외 시장 판매 성장 및 제조 가속화 PeriCoach 치료는 골반 기저근 센터에서 받는 골반 기저근 물리치료와 비교해 훨씬 낮은 비용으로 대등한 효과를 갖는 것으로 임상시험을 통해 확인돼 PeriCoach, 출산 여성과 고령 여성 삶의 질 향상시키고 케어 부담 및 실금용 패드 비용 경감호주 브리즈번, April 01, 2021 (GLOBE NEWSWIRE) — 복압성 요실금 치료용 골반 기저근 운동 시스템 제조사인 호주의 Analytica Limited (ASX:ALT)는 중국과 마카오, 홍콩, 대만 지역 내 제조, 유통, 판매를 위한 합작법인(JV) 계약을 체결했다고 밝혔다. Analytica가 제휴를 맺은 기업은 중국 허베이성에 기반을 둔 Hebei NACOL Bio-Technology Co., Ltd (Nacol)와 Shijiazhuang Biosphere Pty Ltd (Biosphere)다. Nacol의 핵심 주주는 중국 의료기기 제조 및 유통 전문기업인 Heibei Aineng Biological Technology Co., Ltd와 Shijiazhuang YST Medical Supplies Co. Ltd.다. 합작법인은 앞으로 PeriCoach를 중국 국가식품약품감독관리총국(CFDA)에 2등급 의료기기로 등록할 예정이다. CFDA 승인을 획득할...

PeriCoach akan diedarkan melalui rangkaian pusat jagaan pascapartum, hospital, rangkaian farmasi dan platform dalam talian yang diservis oleh rakan kerjasama usaha sama yang meluas. Usaha sama juga akan memanfaatkan rangkaian 30,000 klinisian yang meluas di 100 bandar untuk mengedarkan PeriCoach di China. Perjanjian dibina atas kerjasama pengagihan di Timur Tengah yang sedia ada Analytica untuk memudahkan pertumbuhan dan pengeluaran PeriCoach di pasaran antarabangsa. Percubaan klinikal mengesahkan rawatan PeriCoach tanpa pengawasan adalah setara dengan terapi fizikal lantai pelvis di klinik untuk rawatan inkontinens urinari tekanan, pada kos yang lebih rendah. PeriCoach memberikan penyelesaian yang cekap kos untuk meningkatkan kualiti kehidupan, mengurangkan beban penjagaan dan mengurangkan perbelanjaan pad inkontinens dalam populasi...

O PeriCoach será distribuído por meio de uma extensa rede de centros de atendimento pós-parto, hospitais, redes de farmácias e plataformas on-line atendidas pelos parceiros da joint venture. A joint venture também se beneficiará de uma extensa rede com mais de 30 mil médicos em 100 cidades para distribuir o PeriCoach na China. O acordo agrega à parceria de distribuição que a Analytica já tem no Oriente Médio para facilitar o crescimento e a fabricação do PeriCoach nos mercados internacionais. Os estudos clínicos comprovam que o tratamento não supervisionado com o PeriCoach atinge resultados semelhantes à fisioterapia do assoalho pélvico realizada em clínicas no tratamento da incontinência urinária por estresse, com um custo muito menor. O PeriCoach é uma solução com boa relação custo-benefício que melhora a qualidade de vida e reduz...

PeriCoach se distribuirá en una extensa red de centros de atención posparto, hospitales, cadenas de farmacias y plataformas en línea a los que prestan servicios los socios de la empresa conjunta. La empresa conjunta también aprovechará su extensa red de más de 30 000 médicos en 100 ciudades para distribuir PeriCoach en China. El acuerdo está basado en la asociación de distribución existente de Analytica en el Oriente Medio para facilitar el crecimiento y la fabricación de PeriCoach en los mercados internacionales. Según el ensayo clínico, el tratamiento con PeriCoach sin supervisión está a la altura de la fisioterapia del suelo pélvico que se realiza en las clínicas para tratar la incontinencia urinaria de esfuerzo, a un costo mucho menor. PeriCoach ofrece una solución rentable para mejorar la calidad de vida, aliviar las molestias de...

PeriCoach将通过合资企业合作伙伴提供服务的广泛的产后护理中心、医院、连锁药店和在线平台网络进行分销。 合资企业还将利用100多个城市中超过3万名临床医生组成的广泛网络，在中国分销PeriCoach。 在Analytica公司现有的中东分销合作伙伴关系基础上缔结协议以促进PeriCoach在国际市场的增长和制造。 临床试验证实，非经监督的PeriCoach治疗方法与临床内盆底物理疗法在治疗压力性尿失禁方面具有同样的效果，且成本更低。 PeriCoach提供具有成本效益的解决方案，以提高生活质量、减轻护理负担并减少产后和老龄人群的失禁垫开支。澳大利亚布里斯班, April 01, 2021 (GLOBE NEWSWIRE) — Analytica Limited（澳大利亚证券交易所股票代码：ALT）是澳大利亚用于治疗压力性尿失禁的PeriCoach盆底肌锻炼系统的生产商，该公司签订了一项合资企业（JV）协议，以在中国、澳门、香港和台湾制造、分销和推广该系统。Analytica与位于河北省的河北NACOL Bio-Technology Co., Ltd（Nacol）公司和石家庄Biosphere Pty Ltd（Biosphere）公司达成合作。 Nacol的关键股东包括两家极具经验的中国医疗制造和分销公司：河北Aineng Biological Technology Co., Ltd.和石家庄YST Medical Supplies Co. Ltd.。 该合资企业将向中国食品药品管理局（CFDA）注册PeriCoach为二级医疗器械。获得CFDA批准后，PeriCoach可成为处方治疗器械首先覆盖中国北部地区的医院网络。 向中国市场的扩展将为PeriCoach面向快速增长的产后康复市场及处于早期阶段的预防性老年市场的分销提供支持，目前全球三分之一的女性都面临压力性尿失禁问题。该协议进一步推进了Analytica的战略，在通过与Motion Egypt...

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone – Plinabulin’s MoA is distinct from, yet complementary to that of G-CSF, acting in Week 1 of the chemotherapy cycle, where over 75% of CIN-related complications occur, with G-CSF acting in Week 2 NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating...

TORONTO, March 31, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (CSE: BNKR) (“Bunker Hill” or the “Company) reports that it has filed a Form 10-KT transition report for the six months ended December 31, 2020, consistent with the change in its fiscal year end as announced on February 12, 2021. The report includes the Company’s audited financial statements for the six months ended December 31, 2020, management’s discussion and analysis, and other disclosure including all material events since the change in the Company’s management team approximately one year ago. Sam Ash, CEO of Bunker Hill, stated: “As we look back on our first full year of Bunker Hill under new management, we are proud of the significant milestones that we have accomplished for our investors and stakeholders, including establishing and upgrading our resource,...

SHENZHEN, China, April 01, 2021 (GLOBE NEWSWIRE) — Fangdd Network Group Ltd. (NASDAQ: DUO) (“FangDD” or “the Company”), a leading property technology company in China, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the Securities and Exchange Commission on March 31, 2021, Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.fangdd.com. The Company will also provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About FangDDFangdd Network Group Ltd. (Nasdaq: DUO) is a leading property technology company in China, operating one of the largest online real estate marketplaces in the country. Through innovative...

MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA:8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce today its financial and operational results for the fourth quarter and fiscal year ended December 31st, 2020. “We are happy to announce Q4, and fiscal year end, results for the period ending December 31st, 2020, which continue the historical trends began earlier in the year. Our full year revenues of $18MM reflects the successful processing of backlog from signed contracts previously disclosed. The Board’s choice...